ARA290

Research use only, not for human use.

ARA290 is a nonerythropoietic peptide engineered from erythropoietin,, and used for neurological disease treatment.

ARA290 is a nonerythropoietic peptide engineered from erythropoietin,, and used for neurological disease treatment.(In Vitro):ARA290 enhances the proliferation, migration, and resistance to H2O2-induced apoptosis of endothelial colony-forming cells (ECFCs). ARA290 is an EPO-analog peptide without hematopoietic side-effects but may have neurotrophic and antidepressant effects.(In Vivo):After ECFC transplantation to mice with CLI, a single ARA290 injection enhances the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4?h after transplantation. ARA290 (30 μg/kg, s.c.) prevents progressive worsening of glucose control without affecting body weight of rats. ARA290 significantly decreases glucose AUCs in IPGTT in GK rats. Low-dosage ARA290 (35 μg/kg, i.p.) treatment only slightly attenuates the EAE severity in rats. ARA290-treating group (70 μg/kg, i.p.) significantly delays the onset, decreases the neurologic severity and shortens the duration of EAE in a dose-dependent way.

Cibinetide

Others

Other Targets

——

——

——

1208243-50-8

1257.3

C51H84N16O21

>98% (HPLC)

DMSO : ≥ 34 mg/mL (27.04 mM)

——

(-20℃)

With Ice Pack

≥ 2 years